I bought it yesterday based on the determination that it was near the lowest price.
Among the stocks handling CrisperCas9, it is currently considered the best.
However, when considering gene editing as a fundamental treatment, it is worth keeping in mind that CRISPR-Cas9, for which Universities in Japan hold a patent, may have higher potential in the future.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more